Company news from the 12/05/06 news brief

Share this article:
Savient Pharmaceuticals has filed a lawsuit in the US District Court for the District of New Jersey against Sandoz Pharmaceuticals, a Novartis Pharmaceuticals company and Upsher-Smith Laboratories for infringement of Savient's US patents relating to various methods of using Savient's Oxandrin (oxandrolone tablets). Oxandrin is Savient's oral anabolic agent indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infection, or severe trauma.
Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?